**Call for the funding of research collaborations on major unresolved questions in cancer research**

***Title of the Project (max. 140 characters, e.g. “AKRONYM - …”)***

***Updated Version of April 25th 2023 (see also Application guideline)***

***Please delete italic written text and substitute with your information!***

**Acronym:** *(max. 10 Characters)*

**Project Duration:** (*duration of the project in months)*

**Topic:** *please indicate which module your project is focussing on:*

*Module 1: Epigenome, metabolome, microbiome, and microenvironment (E3M)*

*Module 2: Clinical studies for cellular immunotherapies*

*Module 3: Metastasis*

**Total requested Budget: *(whole consortium, incl. overhead)***

**Team:**

Project Coordinator:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| No. | Name | Institution / Department, address | Function in Project | Signature\* |
| 1 |  |  |  |  |

\* I herewith confirm that the following proposal and all information and data given in the proposal are correct and consent to the use of this data in accordance to the statements of the privacy policy.

Partners(*PIs of the minimum four, maximum 8 Subprojects.* *Extra lines can be inserted as required. Please indicate Partners, which are early career scientists with “(ECS)”)***:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| No. | Name | Institution / Department | Function in Project | Signature\* |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| … |  |  |  |  |
| … |  |  |  |  |
| 8 |  |  |  |  |

\* I herewith confirm that the following proposal and all information and data given in the proposal are correct and consent to the use of this data in accordance to the statements of the privacy policy.

**Five Keywords:***(five keywords highlighting/describing the projects outline)*

**Project description**

*Maximum # of pages for Project description: 8.
(including references, excluding financial table).*

*Maximum # of pages for Study synopsis: 2*

*Maximum # of pages for Appendices: 10*

*Please replace the italicized text with your information.*

**1. Lay abstract** *(max. ½ page)*

***Please note:*** *The lay abstract needs to be written as a plain English summary, such that it is clear, easy to understand, and is easily accessible to a broad lay audience. Avoid the use of highly technical terms. This abstract will be used for support of lay persons involved in the review of these proposals. It may be used later on when providing information to the public concerning the variety of research funded within this call.*

**2. Summary** *(max. 5 pages)*

**2.1 Description of the proposed research**

*This section must start with the relation of the project to the aims of the call, and comprise the description of the overall scientific aims related to one of the three topics of the call, the scientific rationale, the methodology highlighting the novelty, originality**and feasibility as well as the added value at the level of the whole project. Describe the interdisciplinary scientific context of the proposed research network.*

**2.2 Work plan**

*Please describe the work plan, scientific aims and the methodology for each subproject (give also a title to each subproject). Integrate the central research objectives of all subprojects into the description and the way they synergistically interact with each other. Justify the budget proposed. Illustrate the timeframe and milestones of the network as figure (e.g. as Gantt chart).*

**2.3 Organization and coordination of the project**

Please explain the rationale for team make up, the chosen structure and size of the network with respect to the research problem.(Are all relevant prerequisites, expertises and capacities included to address the overall aim ofthe network). *Please describe the concept for coordination and steering of the network. (What structure will be implemented for an efficient cooperation and interdisciplinary networking? How will the network* *be managed? Is there a data management system in place? Which communication channels will be established?). Please give a brief description of ethical and legal considerations relating to the project (e.g. informed consent, data protection, use of animals, intellectual property rights, patenting.*

**3. Impact and output** *(max. 2 pages)*

*Please describe the expected clinical impact and an exploitation concept at the level of the project.*

**4. Patient participation** *(max. ½ page)*

*See section “Beteiligung von Patientinnen und Patienten” in the call text. Please delineate, if applicable, the envisaged patients´ organization to be involved in the project. (max. ½ page)*

**5. Financial overview**

*Please justify in brief your planned expenditures for each subproject for the envisaged duration of the project (maximum of 5 years) (max. 1 page). Please sum up additionally the entire planned expenditures for the envisaged duration in the table below.*

|  |
| --- |
| **Financial table – *“Akronym of the project”*** |
| Subproject (#/title) | Institution | Personnel  | Consumables / equipment / commissions € | Other € (e.g. patient participation, travel, overhead, etc.) | **Total****funding requested€3** |
| # of sci, grad, eng, T, O1 | € |
| 1. *e.g. characterisation of gene X with respect to diseases Y + Z* | e.g. University of… |  |  |  |   |  |
| 2. *e.g. identification of therapeutic-relevant gene Z* | e.g. xyz GmbH |  |  |  |   |  |
| 3. *e.g. data handling* | e.g. University of.. |  |  |  |   |  |
|  |  |  |  |  |  |  |
| **TOTAL** **PROJECT** |  |  |  |  |  |  |

**1**Sci = Scientist, Grad = Graduate student, Eng = Engineer, T = Technician, O = Other; Please calculate your local institutional salaries.**2**Overhead = Gemeinkosten, 20% Projektpauschale. **3**Please calculate requested amount according to funding rate: generally up to 100% of total costs for academia and generally up to 50% of total costs for industry (plus bonuses for KMU, if applicable).

**5.1 Conflict of interest / Other funding**

*Any potential conflict of interest must be disclosed.*

*In case you have already submitted parts of the same request to other institutions or the BMBF, please mention this here. Indicate other external sources which will provide funds, free services or consumables. If this is not the case please declare:*

"A request for funding of this project has not been submitted to any other addressee. In case I submit such a request I will inform the Project Management Agency immediately.”

**6. List of references** *(max. ½ page, font size: 9, single line spacing)*

**Study synopsis**

*If a clinical study is proposed in the project, please fill out the following synopsis (max. 2 pages); if no clinical is planned, please delete this section of the template:*

**Study SYNOPSIS**

|  |  |
| --- | --- |
| **APPLICANT/COORDINATINGINVESTIGATOR** | Name, address, telephone, e-mail*In case of multiple applicants the principal investigator/coordinating investigator of the study who will assume responsibility for conducting the clinical study, should be listed first. See also (*[*https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5\_en.pdf*](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf)*) point 1.19 and 1.34.* |
| **TITLE OF STUDY** | *Descriptive title identifying the study design, population, and interventions to be compared. In case of funding this title shall be quoted in the annual reports of the BMBF.*  |
| **CANCER ENTITY(IES)** | *The type(s) of cancer being studied*  |
| **OBJECTIVE(S)** | *Which principal research questions are to be addressed? Specify clearly the primary hypotheses of the study that determines sample size calculation.*  |
| **INTERVENTIONS** | *Description of the interventions (preventive, diagnostic, or therapeutic) to be compared and/or optimized as well as dose and mode of application, if applicable.*Experimental interventions:Control intervention:Duration of intervention per patient:Follow-up per patient: |
| **KEY INCLUSION AND EXCLUSION CRITERIA** | Key inclusion criteria:Key exclusion criteria:  |
| **OUTCOME(S)** | Primary endpoint:Key secondary endpoint(s):Assessment of safety: |
| **STUDY TYPE** | *e.g. randomized/non-randomized, type of masking (single, double, observer blind), type of controls (active/placebo), parallel group/cross-over* |
| **STATISTICAL ANALYSIS** | Primary endpoint analysis and population:Safety: *Please describe the strategy for assessment of safety issues in the study. Which are relevant safety variables?*Secondary endpoint analysis: |
| **SAMPLE SIZE** | To be assessed for eligibility (n = …)To be allocated to study (n = …)To be analysed (n = …) |
| **STUDY DURATION** | Time for preparation of the study (months):Recruitment period (months):First patient in to last patient out (months):Time for data clearance and analysis (months): Duration of the entire study (months): |
| **PARTICIPATING CENTERS** | To be involved (n): *How many centers will be involved? Please also list the cities.* |
| **PREVIOUS BMBF PROJECT NUMBER** | *If applicable, the BMBF code number of the latest application or of any previous application(s) for project-funding relevant to this study.* |
| **SUBMISSION OF PROPOSAL ELSEWHERE / OTHER FUNDING** | *Please state, if the same or a similar version of this proposal has been submitted in another funding programme, or if you receive any other funding for parts of the study proposed here.*  |

**Appendix**

*Max. 10 pages*

*Eligible are only CVs of PIs with a list of up to five relevant publications within the last five years, demonstrating the competence and qualification to carry out the project (max. 1 page per CV) and one page of LoI of patient representatives involved in the project.*